Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.

Company Growth (employees)
Basel, CH
Size (employees)
119,000 (est)
Novartis was founded in 1996 and is headquartered in Basel, CH

Key People at Novartis

Joseph Jimenez

Joseph Jimenez

Chief Executive Officer
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Paul van Arkel

Paul van Arkel

Head of Corporate Strategy and Healthcare Systems
Peter Elam

Peter Elam

Head of Internal Audit
Erwin Vanhaecke

Erwin Vanhaecke

Head Novartis Group Quality
Michael Willi

Michael Willi

Group Head of Communications
Felix Ehrat

Felix Ehrat

Group General Counsel
Richard Francis

Richard Francis

CEO, Sandoz
Andre Wyss

Andre Wyss

President, Novartis Operations Country President for Switzerland
Juergen Brokatzky-Geiger

Juergen Brokatzky-Geiger

Global Head, Corporate Responsibility for Novartis
Michael Ball

Michael Ball

CEO, Alcon
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Bruno Strigini

Bruno Strigini

CEO, Novartis Oncology
Steven Baert

Steven Baert

Head of Human Resources

Novartis Office Locations

Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
New York, US
230 Park Avenue, 21st Floor
East Hanover, US
1 Health Plazam, Bldg. 101

Novartis Data and Metrics

Novartis Financial Metrics

Novartis's revenue was reported to be $48.5 b in FY, 2016 which is a 2% decrease from the previous period.

Revenue (FY, 2016)

48.5 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

31 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

6.7 b

Market capitalization (31-Jan-2017)

175.5 b

Closing share price (31-Jan-2017)

Novartis's current market capitalization is $175.5 b.
USDFY, 2014FY, 2015FY, 2016


53.6 b49.4 b48.5 b

Revenue growth, %


Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
USDY, 2016


411.2 k
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Patients Reached

972 m965 m

Projects Entering Development Pipeline


Major Submissions (US, EU, JP)


Major Approvals (US, EU, JP)

Show all operating metrics

Novartis Market Value History

Novartis Revenue Breakdown

Novartis Job Categories

Novartis Median Salaries

Source: 453 public H-1B filings from Novartis

Traffic Overview of Novartis

Novartis Online and Social Media Presence

Novartis News and Updates

Watch out: Novartis mulls spin-off of eyecare business

Novartis may spin off its struggling Alcon eye care business as it looks at ways to boost growth The Swiss drugmaker also plans to buy back up to $5bn (£4bn) of shares over the next year in a bid to return to growth by 2018. Alcon has slumped to a $120m loss as fourth-quarter sales dipped. Nov…

Novartis backs off from 2016 date for testing Google’s smart contact lens

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."

Big Tech And Pharma Bet On Cancer Therapy Startups: Celgene, Novartis, Pfizer, and Google’s Investments

Corporate interest in life-science startups developing cancer therapies has been increasing over the years. Corporate-backed deals are up from around 30 in 2012 to nearly 50 so far this year (as of 10/26/16). Apart from big pharma companies like Novartis, … Continued

Novartis Says MS Drug Cut Risk of Disability Advance in Study

"These data are a positive stride forward," says Novartis CMO.
Show more

Novartis Company Life and Culture

You may also be interested in